# US 2019/0314326 A1 · Dilutable formulations of cannabinoids and processes for their preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314326 A1
- Document ID: US20190314326A1
- Status: Published application
- Kind: A1
- Application number: 16/338,273
- Filed: 2017-09-28
- Published: 2019-10-17
- Earliest claimed: 2016-09-29
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
- Inventors: Nissim GARTI; Sharon GARTI LEVI; Rotem EDRI
- Web page: https://patentgrep.com/patent/US20190314326A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 9/4858: {Organic compounds}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are cannabinoid-loaded formulations, as well as processes for their preparation.

## Claims

### Claim 1

A cannabinoid-loaded formulation essentially devoid of water, the formulation comprising at least one oil, at least one hydrophilic surfactant, at least one co-surfactant, and at least 0.1 wt % of at least one cannabinoid.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The cannabinoid-loaded formulation of claim 1, being free of water.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The cannabinoid-loaded formulation of claim 1, wherein said at least one oil is selected from mineral oil, paraffinic oils, vegetable oils, glycerides, esters of fatty acids, liquid hydrocarbons and mixtures thereof; wherein said at least one oil is present in the formulation at an amount of between about 0.5 and 20 wt %

### Claim 8 (depends on 7)

The cannabinoid-loaded formulation of claim 7, wherein said at least one oil is selected from medium-chain triglycerides (MCT), olive oil, soybean oil, canola oil, cotton oil, palmolein, sunflower oil, corn oil, rapeseed oil, grape seeds oil, hemp oil, pomegranate oil, avocado oil, peppermint oil, tomato oil, isopropyl myristate, oleyl lactate, coco caprylocaprate, hexyl laurate, oleyl amine, oleic acid, oleyl alcohol, linoleic acid, linoleyl alcohol, ethyl oleate, hexane, heptanes, nonane, decane, dodecane, D-limonene, neem oil, lavender oil, peppermint oil, anise oil, rosemary oil, sage oil, hibiscus oil, berries oil (any type), menthol, capsaicin, grape seed oil, pumpkin oil, hemp oil and similar essential oils or triglycerides or esters of fatty acids and mixtures thereof.

### Claim 9 (depends on 1)

The cannabinoid-loaded formulation of claim 1, wherein said at least one hydrophilic surfactant is selected from polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monooleate, and polyoxyeyhylene esters of saturated and unsaturated castor oil, ethoxylated monglycerol esters, ethoxylated fatty acids and ethoxylated fatty acids of short and medium and long chain fatty acids; wherein said at least one hydrophilic surfactant is present in the formulation at an amount of between about 30 and 85 wt %.

### Claim 10 (depends on 1)

The cannabinoid-loaded formulation of claim 1, wherein said at least one co-surfactant is selected from polyols, diglycerides, and polyoxyethylenes; wherein said at least one co-surfactant is present in the formulation in an amount of between about 1 and 50 wt %.

### Claim 11 (depends on 1)

The cannabinoid-loaded formulation of claim 1, wherein the ratio between the hydrophilic surfactants and the co-surfactants are between about 1:1 and 6:1 (wt/wt).

### Claim 12 (depends on 1)

The cannabinoid-loaded formulation of claim 1, further comprising at least one solvent and/or at least one phospholipid.

### Claim at position 11

-17. (canceled)

### Claim 18 (depends on 1)

The cannabinoid-loaded formulation of claim 1, comprising between about 0.1 and 12 wt % of said cannabinoid.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The cannabinoid-loaded formulation of claim 1, having an oil droplet size of between about 5 and about 30 nanometers and/or wherein said cannabinoid being geometrically and physically integrated into the oil.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The cannabinoid-loaded formulation of claim 1, wherein the formulation stabilizes the cannabinoid in acidic environments.

### Claim 23 (depends on 22)

The cannabinoid-loaded formulation of claim 22, wherein the acidic environment is gastric fluid.

### Claim 24 (depends on 23)

The cannabinoid-loaded formulation of claim 23, wherein the cannabinoid is CBD, and wherein the formulation reduces the rate of transformation of the CBD into THC.

### Claim 25 (depends on 1)

A process for preparing the cannabinoid-loaded formulation of claim 1, the process comprising mixing a cannabinoid source with a formulation comprising at least one oil, at least one hydrophilic surfactant, and at least one co-surfactant.

### Claim 26 (depends on 25)

The process of claim 25, wherein the mixing is carried out for between about 2 and 30 minutes and/or at a temperature of between about 15 and 60° C.

### Claim 27

(canceled)

### Claim 28 (depends on 25)

The process of claim 25, wherein the cannabinoid source is selected from pure cannabinoid, cannabinoid in crystalline form, a natural cannabinoid source, a cannabinoid extract, and a synthetic cannabinoid.

### Claim at position 23

-30. (canceled)

### Claim 31 (depends on 28)

The process of claim 28, wherein the natural cannabinoid source is a plant from the genus Cannabis.

### Claim at position 25

-34. (canceled)

### Claim 35 (depends on 31)

The process of claim 31, wherein the process further comprises at least one additional step selected from (i) separating between the cannabinoid-loaded formulation and spent cannabinoid source, (ii) heating the cannabinoid source prior to mixing and (iii) homogenizing the formulation and the cannabinoid source after mixing.

### Claim at position 27

-37. (canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising the cannabinoid-loaded formulation of claim 1.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, being in a form selected from a gel, a lotion, oil, soap, a spray, an emulsion, a cream, an ointment, capsules, soft-gel capsules, a patch, or a solution.

### Claim 40 (depends on 38)

The pharmaceutical composition of claim 38, adapted for delivery of said cannabinoid topically, orally, by inhalation, nasally, transdermally, occularly or parenterally into the circulatory system of a subject.

### Claim 41 (depends on 38)

The pharmaceutical composition of claim 38, further comprising a pharmaceutically acceptable carrier and/or a diluent.

### Claim at position 32

-49. (canceled)
